Drilldown: Medicines
Use the filters below to narrow your results.
generic:
Agomelatine (1) ·
Amoxapine (1) ·
Apixaban (1) ·
Asenapine (1) ·
Chlorpromazine (1) ·
Clomipramine (1) ·
Desipramine (1) ·
Droperidol (1) ·
Duloxetine (1) ·
Fluphenazine (1) ·
Iloperidone (1) ·
Imipramine (1) ·
Isocarboxazid (1) ·
Levomilnacipran (1) ·
Loxapine (1) ·
Lurasidone (1) ·
Maprotiline (1) ·
Milnacipran (1) ·
Moclobemide (1) ·
Molindone (1) ·
Nefazodone (1) ·
Paliperidone (1) ·
Perphenazine (1) ·
Phenelzine (1) ·
Pimozide (1) ·
Protriptyline (1) ·
Reboxetine (1) ·
Rivaroxaban (1) ·
Sertraline (1) ·
Thioridazine (1) ·
Thiothixene (1) ·
Tianeptine (1) ·
Tranylcypromine (1) ·
Trifluoperazine (1) ·
Trimipramine (1) ·
Warfarin (1) ·
Ziprasidone (1)
brand:
None (1) ·
Anafranil (1) ·
Aurorix (1) ·
Coumadin (discontinued in US but name in common use), Jantoven (1) ·
Cymbalta, Drizalma Sprinkle, Irenka, Yentreve (1) ·
Edronax (1) ·
Eliquis (1) ·
Fanapt (1) ·
Fetzima (1) ·
Geodon (1) ·
Inapsine (1) ·
Invega (1) ·
Latuda (1) ·
Loxitane (1) ·
Ludiomil (1) ·
Marplan (1) ·
Mellaril (1) ·
Moban (1) ·
Nardil (1) ·
Navane (1) ·
Norpramin (1) ·
Orap (1) ·
Parnate (1) ·
Prolixin (1) ·
Saphris (1) ·
Savella (1) ·
Serzone (1) ·
Stablon (1) ·
Stelazine (1) ·
Surmontil (1) ·
Thorazine (1) ·
Tofranil (1) ·
Trilafon (1) ·
Valdoxan (1) ·
Vivactil (1) ·
Xarelto (1) ·
Zoloft (1)
classes: (Click arrow to add another value)
mechanism:
None (1) ·
Butyrophenone D2 antagonist (1) ·
D2 receptor antagonist; also H1, alpha-1, muscarinic antagonist (1) ·
D2/5-HT2A antagonist (1) ·
D2/5-HT2A antagonist; 5-HT7 antagonist (1) ·
D2/5-HT2A antagonist; active metabolite of risperidone (1) ·
D2/5-HT2A antagonist; SRI and NRI (1) ·
Dibenzoxazepine D2/5-HT2 antagonist (1) ·
Dihydroindolone D2 antagonist (1) ·
Diphenylbutylpiperidine D2 antagonist (1) ·
Irreversible non-selective MAO inhibitor (3) ·
Melatonin receptor agonist; 5-HT2C antagonist (1) ·
Mu-opioid agonist; modulates glutamate AMPA receptors (1) ·
Multi-receptor antagonist (D2, 5-HT2A, H1, alpha) (1) ·
Phenothiazine D2 antagonist (4) ·
Potent serotonin reuptake inhibitor; also NRI (1) ·
Reversible inhibitor of MAO-A (1) ·
Selective norepinephrine reuptake inhibitor (3) ·
Serotonin and norepinephrine reuptake inhibitor (3) ·
Serotonin reuptake inhibitor and 5-HT2A antagonist (1) ·
Serotonin–norepinephrine reuptake inhibition (balanced) (1) ·
Serotonin–norepinephrine reuptake inhibitor (2) ·
Thioxanthene D2 antagonist (1) ·
TrkB/BDNF'"`UNIQ--ref-00000084-QINU`"' '"`UNIQ--vote-00000085-QINU`"' (1) ·
Weak SRI; primarily H1/D2/alpha antagonist (1) ·
'"`UNIQ--vote-000001F6-QINU`"' CYP3A4 (primary) and P-glycoprotein substrate; strong dual inhibitors or inducers materially shift exposure. Reversal: andexanet alfa for life-threatening bleeding; 4F-PCC commonly used off-label when andexanet unavailable'"`UNIQ--ref-000001F7-QINU`"'. (1) ·
'"`UNIQ--vote-0000050D-QINU`"' CYP3A4 (primary) and P-glycoprotein substrate; strong dual inhibitors or inducers materially shift exposure. Reversal: andexanet alfa for life-threatening bleeding; 4F-PCC commonly used off-label when andexanet unavailable'"`UNIQ--ref-0000050E-QINU`"'. (1)
uses:
None (33) ·
Depression, anxiety, neuropathic pain, fibromyalgia, chronic musculoskeletal pain (1) ·
'"`UNIQ--vote-0000001B-QINU`"', '"`UNIQ--vote-0000001C-QINU`"', '"`UNIQ--vote-0000001D-QINU`"', '"`UNIQ--vote-0000001E-QINU`"', '"`UNIQ--vote-0000001F-QINU`"' (1) ·
'"`UNIQ--vote-000001F8-QINU`"', '"`UNIQ--vote-000001F9-QINU`"', '"`UNIQ--vote-000001FA-QINU`"' (1) ·
'"`UNIQ--vote-0000050F-QINU`"', '"`UNIQ--vote-00000510-QINU`"', '"`UNIQ--vote-00000511-QINU`"', '"`UNIQ--vote-00000512-QINU`"' (1)
starting dose:
None (33) ·
25 mg (1) ·
NVAF: 20 mg PO once daily with the evening meal (15 mg if CrCl 15-50); acute VTE: 15 mg BID for 21 days, then 20 mg daily; CAD/PAD: 2.5 mg BID with aspirin (1) ·
NVAF: 5 mg PO BID (2.5 mg BID if 2 of 3: age ≥80, weight ≤60 kg, serum creatinine ≥1.5 mg/dL); acute VTE: 10 mg BID for 7 days, then 5 mg BID (1) ·
Typical 5 mg PO daily; 2.5 mg in elderly, low body weight, malnutrition, hepatic dysfunction. Genotype-guided initial dosing per CPIC/IWPC algorithms (CYP2C9, VKORC1, CYP4F2) is one of the most-established PGx applications in current practice (1)
preparations:
fda max:
routes:
onset:
duration:
halflife:
None (32) ·
36-42 hours (R/S enantiomers differ; S-warfarin is 2-5× more potent and cleared by CYP2C9)'"`UNIQ--ref-00000020-QINU`"' (1) ·
5-9 hours (elderly: 11-13 hours)'"`UNIQ--ref-00000513-QINU`"' (1) ·
~12 hours (1) ·
~12 hours'"`UNIQ--ref-000001FB-QINU`"' (1) ·
~26 h (sertraline; range 13-45 h, longer in females); ~62-104 h (N-desmethylsertraline, weakly active) (1)
bioavailability:
None (32) ·
Absolute bioavailability not precisely characterized; food modestly increases exposure (1) ·
~100% (oral)'"`UNIQ--ref-00000021-QINU`"' (1) ·
~50% (highly variable) (1) ·
~50% (oral; not significantly affected by food)'"`UNIQ--ref-000001FC-QINU`"' (1) ·
~80-100% with food at 15-20 mg doses (10 mg dose: ~80% without food); '''must be taken with food''' at therapeutic doses'"`UNIQ--ref-00000514-QINU`"' (1)
pregnancy:
None (33) ·
'''Contraindicated in pregnancy''' (warfarin embryopathy, fetal hemorrhage) except in mechanical mitral valves where the maternal mortality of alternative agents may exceed fetal risk.'"`UNIQ--ref-00000022-QINU`"' (1) ·
Avoid in pregnancy; switch to LMWH. Crosses placenta; warfarin-class concerns about fetal hemorrhage and teratogenicity make heparins the preferred class.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Category C (1) ·
Category C'"`UNIQ--ref-0000008F-QINU`"' (1)
Showing below up to 37 results in range #1 to #37.